These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study]. Chaná P; Fierro A; Reyes-Parada M; Sáez-Briones P Rev Med Chil; 2003 Jun; 131(6):623-31. PubMed ID: 12942590 [TBL] [Abstract][Full Text] [Related]
3. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa. Metman LV; Hoff J; Mouradian MM; Chase TN Mov Disord; 1994 Jul; 9(4):463-5. PubMed ID: 7969216 [TBL] [Abstract][Full Text] [Related]
4. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222 [TBL] [Abstract][Full Text] [Related]
7. A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100). Cedarbaum JM; Kutt H; McDowell FH Neurology; 1989 Nov; 39(11 Suppl 2):38-44; discussion 59. PubMed ID: 2586762 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Yeh KC; August TF; Bush DF; Lasseter KC; Musson DG; Schwartz S; Smith ME; Titus DC Neurology; 1989 Nov; 39(11 Suppl 2):25-38. PubMed ID: 2685649 [TBL] [Abstract][Full Text] [Related]
9. Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures. Pahwa R; Lyons K; McGuire D; Silverstein P; Zwiebel F; Robischon M; Koller WC Mov Disord; 1997 Sep; 12(5):677-81. PubMed ID: 9380047 [TBL] [Abstract][Full Text] [Related]
10. Controlled-release carbidopa/levodopa (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: clinical and pharmacokinetic observations. Deleu D; Jacques M; Michotte Y; Ebinger G Neurology; 1989 Nov; 39(11 Suppl 2):88-92; discussion 95. PubMed ID: 2685654 [TBL] [Abstract][Full Text] [Related]
11. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Olanow CW; Fahn S; Muenter M; Klawans H; Hurtig H; Stern M; Shoulson I; Kurlan R; Grimes JD; Jankovic J Mov Disord; 1994 Jan; 9(1):40-7. PubMed ID: 8139604 [TBL] [Abstract][Full Text] [Related]
12. Double-blind comparison of standard Sinemet and Sinemet CR in patients with mild-to-moderate Parkinson's disease. Feldman RG; Mosbach PA; Kelly MR; Thomas CA; Saint Hilaire MH Neurology; 1989 Nov; 39(11 Suppl 2):96-101; discussion 105. PubMed ID: 2685655 [TBL] [Abstract][Full Text] [Related]
13. Superior clinical efficacy of Sinement CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open and a double-blind, double-dummy, multicenter treatment evaluation. Dutch Sinement CR Study Group. Wolters EC; Horstink MW; Roos RA; Jansen EN Adv Neurol; 1993; 60():648-52. PubMed ID: 8420204 [No Abstract] [Full Text] [Related]
14. Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: A single-dose, double-blind, double-dummy, placebo-controlled, crossover trial. Ondo WG; Shinawi L; Moore S Mov Disord; 2010 Dec; 25(16):2724-7. PubMed ID: 20925074 [TBL] [Abstract][Full Text] [Related]
15. Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations. Jankovic J; Schwartz K; Vander Linden C Mov Disord; 1989; 4(4):303-9. PubMed ID: 2682215 [TBL] [Abstract][Full Text] [Related]
16. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease. Hauser RA; Ellenbogen AL; Metman LV; Hsu A; O'Connell MJ; Modi NB; Yao HM; Kell SH; Gupta SK Mov Disord; 2011 Oct; 26(12):2246-52. PubMed ID: 21755537 [TBL] [Abstract][Full Text] [Related]
17. Treatment of early Parkinson's disease with controlled-release levodopa preparations. Rinne UK; Rinne JO Neurology; 1989 Nov; 39(11 Suppl 2):78-81; discussion 95. PubMed ID: 2586766 [TBL] [Abstract][Full Text] [Related]
18. Development and progression of motor fluctuations and side effects in Parkinson's disease: comparison of Sinemet CR versus carbidopa/levodopa. Goetz CG; Tanner CM; Gilley DW; Klawans HL Neurology; 1989 Nov; 39(11 Suppl 2):63-6; discussion 72-3. PubMed ID: 2586764 [TBL] [Abstract][Full Text] [Related]
19. Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment. Zimmerman TR; Sage JI; Lang AE; Mark MH Mov Disord; 1994 Mar; 9(2):173-7. PubMed ID: 8196678 [TBL] [Abstract][Full Text] [Related]
20. Clinical studies with and pharmacokinetic considerations of sustained-release levodopa. LeWitt PA Neurology; 1992 Jan; 42(1 Suppl 1):29-32; discussion 57-60. PubMed ID: 1549198 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]